- Email: [email protected]
Use of a gonadotropin-releasing hormone agonist during ovarian stimulation leads to significant concentrations of peptide in follicular fluids
304
Cìtations front the Literature
in hypogonadotropic hypogonadic males, leading to a greater testicular growth than T preparations. Therefore, hCG treatment may have an advantageous effect on the eventual induction of fertility with human menopausal gonadotropin. Hyperprolactinemis Report of two cases
in clinically asymptomatic,
fertile men:
Colon JM; Ginsburg F; Schmidt CL; Weiss G Divtsion of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Medicine and Dentistry, Newark, NJ; USA Obstetrics and Gynecology/74/3 11SUPPL. (510-513)/1989/ Although the role of prolactin (PRL) in men is undefined, hyperprolactinemia has been associated with decreased reproductive potential. Two healthy, fertile, asymptomatic men with hyperprolactinemia are reported. Both men had normal puberty. Both were euthyroid and had normal gonadotropin levels and androgen profiles. Semen analyses were normal and both had fathered children. The serum RL leve1 (mean 2 standard error of the mean) (N = 5) of subject 1 was 48 f 12 ng/mL, and of subject 2 was 214 f 5 ng/mL. Sella turcica computed tomography stans with contrast were normal. The two subjects underwent a thyrotropin-releasing hormone stimulation test. Serum PRL and TSH were measured by radioimmunoassay. At time 0 and at 15 minutes, PRL bioactivity was measured in the Nb2 node rat lymphoma assay. Both subjects showed a normal TSH response to thyrotropin-releasing hormone. Subject 1 had baseline PRL immunoactivity and bioactivity measuring 41 and 50 ng/mL, respectively, peaking at 76 and 70 ng/ mL 15 minutes after infusion of thyrotropin releasing hormone. Subject 2 had baseline PRL immunoactivity of 200 ng/ mL and bioactivity of 67 ng/mL, neither of which were altered by infusion of thyrotropin-releasing hormone. Administration of L-dopa decreased the serum PRL of subject 1 from 33 to 7 ng/mL, but had no clinically significant effect in subject 2. Prolactin and gonadotropin secretion may be dissociated in men so that hyperprolactinemia may not always manifest as reproductive dysfunction. Use of a gonadotropin-releasing hormone agonist during ovarian stimulation leads to significant concentrations of peptide in follicular fluids
Loumaye E; Coen G; Pampfer S; Vankrieken L; Thomas K Physiologv of Human Reproduction Research Unit, Department of Obstetrics and Gynecology, University of Louvain, B1200 Brussels; Belgium Fertility and Sterility/52/2 (256-263)/1989/ The penetration of a gonadotropin-releasing hormone agonist (GnRH-a), Buserelin (Hoechst AG, Frankfurt, West Germany), into human follicular fluids (FF) was studied by means of a radioimmunoassay (RIA) and a bioassay. Acute nasal administration of a therapeutic dose of Buserelin (300 and 600 mu g) before the ovum pickup for in vitro fertilization leads to significant concentrations of Buserelin in one-third of the FF. These concentrations ranged between 28 and 124 pg/ ml, which represents 10% to 50% of the serum concentrations achieved in these patients. Follicular penetration of this agonist Znt J Gynecol Obstet 31
is time-dependent. Chronic administration during the follicular phase leads to low but significant concentrations of peptide 36 hours after the last inhalation. A very good correlation was observed between the RIA and the bioassay. This demonstrates the accuracy and the specificity of the RIA. In addition, it indicates that the Buserelin that reaches follicles is intact and is not the inactive product of degradation. Intranasal administration of Buserelin stopped 35 hours before ovum pickup appears to be an adequate way of minimizing the exposure of maturing oocytes to the GnRH-a. A pharmacodynamic comparison of human urinary folliclestimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome
Anderson RE; Cragun JM; Chang RJ; Stanczyk FZ; Lobo RA Department of Obstetrics and Gynecology, University of Southern Cahfornia, Los Angeles, CA; USA Fertility and Sterility/52/2 (216-220)/1989/ We performed a pharmacodynamic comparison of human urinary follicle-stimulating hormone (hFSH) and human menopausal gonadotropin (hMG) to characterize differences in the bioavailability of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) as wel1 as to compare estrogen responses in normal women and those with polycystic ovary syndrome (PCOS). Ten women with PCOS and ten normal ovulatory controls were randomized to receive a single dose (2 ampules) of either hFSH or hMG. Serum LH decreased significantly following hFSH with responses occurring earlier in controls (24.5 f 10.9% after 30 minutes) than in PCOS patients (27.3 f 7.5% after 18 hours). After hMG, LH increased only in controls (33.8 f 16.3%). An FSH increment following hFSH was observed in both PCOS patients (54.7 rr 24.8%) and controls (74.6 f 36.8%), with peak responses at 6 and 4 hours, respectively. However, after hMG, FSH increased only in controls. The LH/FSH ratio after hFSH decreased, with the nadir at 18 hours (1.438 f 0.183) being similar to baseline LH/FSH ratios of controls (1.433 f 0.341). Serum estradiol (E,) increased following hMG, with peak responses after 18 hours, in both PCOS patients (75.4 f 28.6%) and controls (88.5 f 32.5%). The peak E, response to hGSH was observed to be earlier in PCOs patients (147 f 34%), occurring after 12 hours, compared with controls (58 f 29% after 18 hours). Two patients with hypergonadotropic pituitary hyperplasia
ovarian failure due to
Okuda K; Yoshikawa M; Ushiroyama T; Sugimoto 0; Maeda T; Mori H Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569; Japan Obstetrics and Gynecology/74/3 11SUPPL. (498-501)/1989/ Two patients with hypergonadotropic ovarian failure were examined. Plasma levels of LH and FSH were markedly elevated to over 113 mIU/mL (Second International Reference Preparation - human menopausal gonadotropin standard), but the FSH/LH ratio was 1 or less in both women. The plasma estradiol (E2) leve1 was 65 pg/mL in one woman before medication, and in the other increased from below 25 to 130 pg/mL after large dose of clomiphene citrate treatment. The
Cìtations front the Literature
in hypogonadotropic hypogonadic males, leading to a greater testicular growth than T preparations. Therefore, hCG treatment may have an advantageous effect on the eventual induction of fertility with human menopausal gonadotropin. Hyperprolactinemis Report of two cases
in clinically asymptomatic,
fertile men:
Colon JM; Ginsburg F; Schmidt CL; Weiss G Divtsion of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Medicine and Dentistry, Newark, NJ; USA Obstetrics and Gynecology/74/3 11SUPPL. (510-513)/1989/ Although the role of prolactin (PRL) in men is undefined, hyperprolactinemia has been associated with decreased reproductive potential. Two healthy, fertile, asymptomatic men with hyperprolactinemia are reported. Both men had normal puberty. Both were euthyroid and had normal gonadotropin levels and androgen profiles. Semen analyses were normal and both had fathered children. The serum RL leve1 (mean 2 standard error of the mean) (N = 5) of subject 1 was 48 f 12 ng/mL, and of subject 2 was 214 f 5 ng/mL. Sella turcica computed tomography stans with contrast were normal. The two subjects underwent a thyrotropin-releasing hormone stimulation test. Serum PRL and TSH were measured by radioimmunoassay. At time 0 and at 15 minutes, PRL bioactivity was measured in the Nb2 node rat lymphoma assay. Both subjects showed a normal TSH response to thyrotropin-releasing hormone. Subject 1 had baseline PRL immunoactivity and bioactivity measuring 41 and 50 ng/mL, respectively, peaking at 76 and 70 ng/ mL 15 minutes after infusion of thyrotropin releasing hormone. Subject 2 had baseline PRL immunoactivity of 200 ng/ mL and bioactivity of 67 ng/mL, neither of which were altered by infusion of thyrotropin-releasing hormone. Administration of L-dopa decreased the serum PRL of subject 1 from 33 to 7 ng/mL, but had no clinically significant effect in subject 2. Prolactin and gonadotropin secretion may be dissociated in men so that hyperprolactinemia may not always manifest as reproductive dysfunction. Use of a gonadotropin-releasing hormone agonist during ovarian stimulation leads to significant concentrations of peptide in follicular fluids
Loumaye E; Coen G; Pampfer S; Vankrieken L; Thomas K Physiologv of Human Reproduction Research Unit, Department of Obstetrics and Gynecology, University of Louvain, B1200 Brussels; Belgium Fertility and Sterility/52/2 (256-263)/1989/ The penetration of a gonadotropin-releasing hormone agonist (GnRH-a), Buserelin (Hoechst AG, Frankfurt, West Germany), into human follicular fluids (FF) was studied by means of a radioimmunoassay (RIA) and a bioassay. Acute nasal administration of a therapeutic dose of Buserelin (300 and 600 mu g) before the ovum pickup for in vitro fertilization leads to significant concentrations of Buserelin in one-third of the FF. These concentrations ranged between 28 and 124 pg/ ml, which represents 10% to 50% of the serum concentrations achieved in these patients. Follicular penetration of this agonist Znt J Gynecol Obstet 31
is time-dependent. Chronic administration during the follicular phase leads to low but significant concentrations of peptide 36 hours after the last inhalation. A very good correlation was observed between the RIA and the bioassay. This demonstrates the accuracy and the specificity of the RIA. In addition, it indicates that the Buserelin that reaches follicles is intact and is not the inactive product of degradation. Intranasal administration of Buserelin stopped 35 hours before ovum pickup appears to be an adequate way of minimizing the exposure of maturing oocytes to the GnRH-a. A pharmacodynamic comparison of human urinary folliclestimulating hormone and human menopausal gonadotropin in normal women and polycystic ovary syndrome
Anderson RE; Cragun JM; Chang RJ; Stanczyk FZ; Lobo RA Department of Obstetrics and Gynecology, University of Southern Cahfornia, Los Angeles, CA; USA Fertility and Sterility/52/2 (216-220)/1989/ We performed a pharmacodynamic comparison of human urinary follicle-stimulating hormone (hFSH) and human menopausal gonadotropin (hMG) to characterize differences in the bioavailability of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) as wel1 as to compare estrogen responses in normal women and those with polycystic ovary syndrome (PCOS). Ten women with PCOS and ten normal ovulatory controls were randomized to receive a single dose (2 ampules) of either hFSH or hMG. Serum LH decreased significantly following hFSH with responses occurring earlier in controls (24.5 f 10.9% after 30 minutes) than in PCOS patients (27.3 f 7.5% after 18 hours). After hMG, LH increased only in controls (33.8 f 16.3%). An FSH increment following hFSH was observed in both PCOS patients (54.7 rr 24.8%) and controls (74.6 f 36.8%), with peak responses at 6 and 4 hours, respectively. However, after hMG, FSH increased only in controls. The LH/FSH ratio after hFSH decreased, with the nadir at 18 hours (1.438 f 0.183) being similar to baseline LH/FSH ratios of controls (1.433 f 0.341). Serum estradiol (E,) increased following hMG, with peak responses after 18 hours, in both PCOS patients (75.4 f 28.6%) and controls (88.5 f 32.5%). The peak E, response to hGSH was observed to be earlier in PCOs patients (147 f 34%), occurring after 12 hours, compared with controls (58 f 29% after 18 hours). Two patients with hypergonadotropic pituitary hyperplasia
ovarian failure due to
Okuda K; Yoshikawa M; Ushiroyama T; Sugimoto 0; Maeda T; Mori H Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569; Japan Obstetrics and Gynecology/74/3 11SUPPL. (498-501)/1989/ Two patients with hypergonadotropic ovarian failure were examined. Plasma levels of LH and FSH were markedly elevated to over 113 mIU/mL (Second International Reference Preparation - human menopausal gonadotropin standard), but the FSH/LH ratio was 1 or less in both women. The plasma estradiol (E2) leve1 was 65 pg/mL in one woman before medication, and in the other increased from below 25 to 130 pg/mL after large dose of clomiphene citrate treatment. The